<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04618718</url>
  </required_header>
  <id_info>
    <org_study_id>CIP_00105</org_study_id>
    <nct_id>NCT04618718</nct_id>
  </id_info>
  <brief_title>The PROTEMBO C Trial</brief_title>
  <official_title>Cerebral Protection in Transcatheter Aortic Valve Replacement - The PROTEMBO C Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Protembis GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MAXIS Medical, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Protembis GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PROTEMBO C Trial is an international, multi-center, single arm, non-inferiority study of&#xD;
      the safety and performance of using the ProtEmbo System for cerebral embolic protection in&#xD;
      subjects with severe native aortic valve stenosis indicated for TAVR.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 31, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of participants with MACCE Events</measure>
    <time_frame>30 days post-procedure</time_frame>
    <description>Number of participants experiencing a Major Adverse Cardiac and Cerebrovascular Event (MACCE) defined by VARC-2 including all-cause mortality, all stroke, life-threatening or disabling bleeding, vascular injury and acute kidney injury (stage 2 or 3) within 30 days of the procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of participants in whom technical success was achieved</measure>
    <time_frame>During the procedure</time_frame>
    <description>Number of participants in whom technical success was achieved during the procedure. Technical success is defined as the ability to safely deliver, deploy, and remove the device, ability to secure positioning and stability of the position throughout the transcatheter intracardiac procedure and ability to deflect embolic material as assessed by adequate coverage while not impeding blood flow, deployed and removed and positioning and stability of the device</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy-MR Imaging: Comparison between the median new lesion volume in the brain</measure>
    <time_frame>2-7 days post-procedure</time_frame>
    <description>Comparison between the median new lesion volume in the brain assessed by diffusion weighted magnetic resonance images (DW-MRI) at 2-7 days and historical data; the total new lesion volume is defined as the sum of all diffusion-positive new cerebral lesions in post-procedural DW-MRI relative to the pre-TAVR DW-MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite rate of death or all strokes</measure>
    <time_frame>3 days post-procedure</time_frame>
    <description>Death or all stroke according to VARC-2 criteria (to define occurrence and type stroke) within 3 days (72 hours) of the TAVR procedure compared to historical data</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Valvular Heart Disease</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ProtEmbo device will be used as distal protection device in subjects undergoing TAVR</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>cerebral embolic protection during TAVR</intervention_name>
    <description>The ProtEmbo system is an adjunctive device placed in the central arterial system at the beginning of a TAVR procedure to deflect embolic particles during the procedure and removed following the completion of the procedure.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The heart team recommends transcatheter valve aortic valve replace consistent with the&#xD;
             2017 ESC/EACTS Guidelines for the management of valvular heart disease.&#xD;
&#xD;
          2. Compatible left subclavian artery (≥ 4 mm diameter) without significant stenosis (&gt;&#xD;
             70%) and distance between the origin of left subclavian artery and valve plain of ≥&#xD;
             90mm as determined by Multi-Slice Computed Tomography (MSCT) scan or equivalent&#xD;
             imaging modality.&#xD;
&#xD;
          3. The subject and the treating physician agree that the subject will undergo the&#xD;
             scheduled pre-procedural testing and return for all required post-procedure follow-up&#xD;
             visits.&#xD;
&#xD;
          4. The subject is able to provide informed consent, has been informed of the nature of&#xD;
             the trial, agrees to its provisions and has provided written informed consent as&#xD;
             approved by the relevant regulatory authority of the respective clinical site.&#xD;
&#xD;
          5. Subject is a minimum of 18 years of age.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General:&#xD;
&#xD;
          1. Left upper limb vasculature in the left extremity precluding 6Fr sheath radial /&#xD;
             brachial / subclavian access.&#xD;
&#xD;
          2. Inadequate circulation to the left extremity as evidenced by signs of artery occlusion&#xD;
             (modified Allen's test) or absence of radial/brachial pulse.&#xD;
&#xD;
          3. Hemodialysis shunt, graft, or arterio-venous fistula involving the upper extremity&#xD;
             vasculature.&#xD;
&#xD;
          4. TAVR conducted via other than transfemoral access (subclavian, axillar, transapical,&#xD;
             transaortic, carotid or transcaval).&#xD;
&#xD;
          5. Evidence of an acute myocardial infarction ≤ 1 month before the intended treatment.&#xD;
&#xD;
          6. Aortic valve is a congenital unicuspid or bicuspid valve.&#xD;
&#xD;
          7. Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant&#xD;
             aortic regurgitation &gt;3+).&#xD;
&#xD;
          8. Any therapeutic invasive cardiac procedure resulting in a permanent implant that is&#xD;
             performed within 30 days of the index procedure (unless part of planned strategy for&#xD;
             treatment of concomitant coronary artery disease).&#xD;
&#xD;
          9. Blood dyscrasias as defined: Leukopenia, acute anemia, thrombocytopenia, history of&#xD;
             bleeding diathesis or coagulopathy.&#xD;
&#xD;
         10. Hemodynamic instability requiring inotropic support or mechanical heart assistance.&#xD;
&#xD;
         11. Need for emergency surgery for any reason.&#xD;
&#xD;
         12. Severe hypertrophic cardiomyopathy with or without obstruction.&#xD;
&#xD;
         13. Severe ventricular dysfunction with LVEF ≤30%.&#xD;
&#xD;
         14. Echocardiographic evidence of intracardiac or aortic mass, thrombus, or vegetation.&#xD;
&#xD;
         15. Symptomatic or asymptomatic severe (≥ 70%) occlusive carotid disease requiring&#xD;
             concomitant CEA / stenting.&#xD;
&#xD;
         16. Subject has undergone carotid stenting or carotid endarterectomy within the previous 6&#xD;
             weeks.&#xD;
&#xD;
         17. Active peptic ulcer or upper GI bleeding within the prior 6 months.&#xD;
&#xD;
         18. A known hypersensitivity or contraindication to aspirin, heparin, ticlopidine, or&#xD;
             clopidogrel, device component material, or sensitivity to contrast media, which cannot&#xD;
             be adequately premedicated.&#xD;
&#xD;
         19. Recent (within 6 months) CVA or a TIA.&#xD;
&#xD;
         20. Renal insufficiency (creatinine &gt; 3.0 mg / dL or GFR &lt; 30) and / or renal replacement&#xD;
             therapy at the time of screening.&#xD;
&#xD;
         21. Life expectancy &lt; 12 months due to non-cardiac co-morbid conditions.&#xD;
&#xD;
         22. Subjects in whom anti-platelet and / or anticoagulant therapy is contraindicated, or&#xD;
             who will refuse transfusion.&#xD;
&#xD;
         23. Subjects who have active bacterial endocarditis or other active infections.&#xD;
&#xD;
         24. Currently participating in an investigational drug or another device study.&#xD;
&#xD;
         25. Subjects who have a planned treatment with any other investigational device or&#xD;
             procedure during the study follow-up period (30 days).&#xD;
&#xD;
         26. Subjects with planned concomitant surgical or transcatheter ablation for Atrial&#xD;
             Fibrillation during the study follow-up period (30 days).&#xD;
&#xD;
         27. Any subject with a balloon valvuloplasty (BAV) within 30 days of the procedure.&#xD;
&#xD;
         28. Subject is a woman of child-bearing potential.&#xD;
&#xD;
         29. Patient with Heparin-Induced Thrombocytopenia Syndrome.&#xD;
&#xD;
         30. Inner diameter of aortic arch is less than 25mm.&#xD;
&#xD;
         31. Brachiocephalic trunk originating from the aortic arch that splits into the bilateral&#xD;
             subclavian arteries and a bicarotid trunk (Origin D).&#xD;
&#xD;
         32. Hepatic failure (defined as liver enzyme elevations two times the upper limit of&#xD;
             normal) or active infectious hepatitis&#xD;
&#xD;
         33. Cardiogenic shock or severe hypotension (systolic blood pressure &lt; 90 mm Hg) at the&#xD;
             time of the index procedure&#xD;
&#xD;
         34. Subjects who have a planned concomitant cardiac surgical or interventional procedure&#xD;
             (e.g., coronary revascularization) during the TAVI procedure&#xD;
&#xD;
         35. Subjects who have a pre-existing prosthetic heart valve in any position&#xD;
&#xD;
        Neurological:&#xD;
&#xD;
          1. Subject had active major psychiatric disease.&#xD;
&#xD;
          2. Subject has severe visual, auditory, or learning impairment and is unable to&#xD;
             comprehend English or local language and therefore unable to be consented for the&#xD;
             study.&#xD;
&#xD;
          3. Subjects with neurodegenerative or other progressive neurological disease or history&#xD;
             of significant head trauma followed by persistent neurologic defaults or known&#xD;
             structural brain abnormalities.&#xD;
&#xD;
        Angiographic:&#xD;
&#xD;
          1. Excessive tortuosity or severe peripheral arterial disease in the left radial /&#xD;
             brachial / subclavian artery preventing ProtEmbo System access and insertion.&#xD;
&#xD;
          2. Subject whose left radial / brachial / subclavian artery reveals significant stenosis,&#xD;
             calcification, ectasia, dissection, occlusion or aneurysm, in particular at or within&#xD;
             3 cm of the aortic ostium.&#xD;
&#xD;
          3. Subject with significant stenosis, ectasia, dissection, or aneurysm in the ascending&#xD;
             aorta or in the aortic arch, or with abnormal aortic arch angulation or abnormal&#xD;
             anatomical conditions of the aorta.&#xD;
&#xD;
        Magnetic Resonance Imaging:&#xD;
&#xD;
          1. Subject Body Mass Index (BMI) precluding imaging in scanner.&#xD;
&#xD;
          2. Contraindications to MRI (subjects with any implantable temporary or permanent&#xD;
             pacemaker or defibrillator, metal implants in field of view, metallic fragments,&#xD;
             clips, or devices in the brain or eye before TAVR procedure).&#xD;
&#xD;
          3. Subjects who have a high risk of complete AV block after TAVR, with the need of&#xD;
             permanent pacemaker (e.g. subjects with preexisting bifascicular block or complete&#xD;
             right bundle branch block plus any degree of AV block).&#xD;
&#xD;
          4. Planned implantation of a pacemaker or defibrillator implantation within the first 4&#xD;
             days after TAVR.&#xD;
&#xD;
          5. Claustrophobia precluding MRI scanning.&#xD;
&#xD;
          6. No scanner hardware, software, coil or protocol changes during the course of the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Karl von Mangoldt</last_name>
    <phone>+4924199033622</phone>
    <email>kvm@protembis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Conrad Rasmus</last_name>
    <phone>+4924199033622</phone>
    <email>cr@protembis.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Brüder Trier</name>
      <address>
        <city>Trier</city>
        <state>Rhineland-Palatinate</state>
        <zip>54292</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silke Plattfaut</last_name>
      <phone>+49 651 208 2776</phone>
      <email>s.plattfaut@bk-trier.de</email>
    </contact>
    <investigator>
      <last_name>Nikos Werner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig-Universitätsklinik für Kardiologie-Helios</name>
      <address>
        <city>Leipzig</city>
        <state>Saxony</state>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Funkat, Dr</last_name>
      <phone>+49 341 8651559</phone>
      <email>info@leipzig-heart.de</email>
    </contact>
    <investigator>
      <last_name>Mohamed Abdel-Wahab, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petra Röthgen</last_name>
      <phone>+49 431-500-22917</phone>
      <email>Petra.roethgen@uksh.de</email>
    </contact>
    <investigator>
      <last_name>Derk Frank, Prof MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein (UKSH)</name>
      <address>
        <city>Lübeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrin Schönhoff</last_name>
      <phone>+49 451 500 44667</phone>
      <email>Katrin.Schoenhoff@uksh.de</email>
    </contact>
    <investigator>
      <last_name>Tobias Schmidt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pauls Stradins Clinical University Hospital</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alona Grave</last_name>
      <phone>+37129419942</phone>
      <email>alona.g@inbox.lv</email>
    </contact>
    <investigator>
      <last_name>Andrejs Erglis, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdansk</city>
        <zip>80-214</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dariusz Jagielak, Dr.</last_name>
      <phone>+48 509487577</phone>
      <email>dariusz.jagielak@gumed.edu.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny Przemienienia Panskiego Poznan University of Medical Sciences</name>
      <address>
        <city>Poznań</city>
        <zip>61-848</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marek Grygier, Dr</last_name>
      <phone>+48618549228</phone>
      <email>marek.grygier@skpp.edu.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Interventional Cardiology Warsaw Institute of Cardiology</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maciej Dabrowski</last_name>
      <email>macidabro@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Adam Adam Witkowski, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Latvia</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 20, 2020</study_first_submitted>
  <study_first_submitted_qc>November 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2020</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TAVR</keyword>
  <keyword>cerebral embolic protection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

